5-苄氧基嘧啶-2-胺 | 42783-58-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-苄氧基嘧啶-2-胺
• 中文别名: 2-氨基-5-(苯甲氧基)嘧啶
• 英文名称: 5-(benzyloxy)pyrimidin-2-amine
• 英文别名: 2-amino-5-benzyloxy-pyrimidine；2-Amino-5-benzyloxy-pyrimidin；5-benzyloxy-2-aminopyrimidine；5-benzyloxy-pyrimidin-2-ylamine；5-phenylmethoxypyrimidin-2-amine
• CAS: 42783-58-4
• 化学式: C₁₁H₁₁N₃O
• 分子量: 201.228
• InChiKey: BRIAQLVXVQRDLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  5-苄氧基嘧啶-2-胺 在 亚硝酸特丁酯 、 苄基三甲基溴化铵 作用下， 以36%的产率得到5-(benzyloxy)-2-bromopyrimidine
  参考文献：
  名称：

  用于探测肽和蛋白质中质子耦合电子转移过程的酪氨酸类似物

  摘要：

  已经制备并表征了一系列类似于酪氨酸但在芳醇侧链的物理化学性质上不同的氨基酸。这些化合物有望用于理解肽和蛋白质中长程质子耦合电子转移过程中的结构、热力学和动力学之间的关系。通过用苯酚代替吡啶醇和嘧啶醇部分，可以诱导酪氨酸侧链的酸度、氧化还原电位和 OH 键强度的系统变化。通过在酚羟基邻位引入甲基和叔丁基取代基，可以进一步调节。非天然氨基酸是通过 Pd 催化交叉偶联制备的，相应的卤代芳醇被保护为苄基醚，与衍生自 N-Boc L-丝氨酸羧甲基酯的有机锌试剂交叉偶联。随后通过催化氢化的脱苄基以良好的产率得到酪氨酸类似物。分光光度法滴定显示约酪氨酸 pK(a) 减少。每个包含的氮原子 1.5 log 单位，以及 ca 的氧化（峰值）电位相应增加。分别为 200 mV。总而言之，这里描述的六种新氨基酸具有酚样侧链，其 pK(a) 的范围为 7.0 到大于 10，氧化（峰值）电位范围在 600 mV 左右生理pH值。进行自由基平衡

  DOI：

  10.1021/ja907921w
• 作为产物：
  描述：

  苄氧基乙醛二乙基乙缩醛 在 五氯化磷 、 sodium hydride 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 74.75h， 生成 5-苄氧基嘧啶-2-胺
  参考文献：
  名称：

  NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME

  摘要：

  一个由以下通用公式（I）表示的化合物，其中R1、R2、R3、R4和R5代表氢原子、卤素（低烷基）基团、氰基团等，R6代表烷基基团、环烷基基团等，R7、R8、R9和R10代表氢原子、卤素原子、低烷基基团、卤素（低烷基）基团等，R11和R12代表氢原子、低烷基基团、（低环烷基）（低烷基）基团等，R13代表氢原子、卤素原子、低烷氧基团等，具有对胆固醇酯转移蛋白（CETP）具有强大抑制活性的化合物。

  公开号：

  US20090082352A1

文献信息

• NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS
  申请人：KADOR PETER F.

  公开号：US20140235858A1

  公开（公告）日：2014-08-21

  The neuroprotective multifunctional antioxidants are compounds that contain a 2-diacetylamino-5-hydroxypyrimidine moiety, having the structural formula: wherein R 1 is CH 2 or C 2 H 4 ; R 2 is H or —OR 4 where R 4 is H or aryl; and R 3a and R 3b are independently selected from the group consisting of H and —O-alkyl. The antioxidants are orally bioavailable metal-attenuating multifunctional antioxidants that can independently attenuate transition metals, as well as scavenger free radicals. The multifunctional antioxidant compounds, by their ability to independently chelate metals, such as Fe, Cu or Zn, and scavenge free radicals generated from different sources, are neuroprotective and are beneficial for the treatment of various neurological disorders, such as Alzheimer's disease, Parkinson's disease, ALS, traumatic brain injury, ocular disorders, such as cataract, glaucoma, age-related macular degeneration and other retinal degeneration, as well as for reducing the progression of diabetic complications.

  神经保护多功能抗氧化剂是含有2-二乙酰氨基-5-羟基嘧啶基团的化合物，具有以下结构式： 其中R1为CH2或C2H4；R2为H或—OR4，其中R4为H或芳基；R3a和R3b分别独立地选自H和—O-烷基的组。这些抗氧化剂是口服可利用的金属减弱多功能抗氧化剂，可以独立减弱过渡金属，以及清除自由基。由于这些多功能抗氧化剂化合物具有独立螯合金属（如Fe、Cu或Zn）和清除来自不同来源产生的自由基的能力，它们具有神经保护作用，并有助于治疗各种神经系统疾病，如阿尔茨海默病、帕金森病、肌萎缩侧索硬化症、创伤性脑损伤、眼部疾病（如白内障、青光眼、老年性黄斑变性和其他视网膜变性），以及减缓糖尿病并发症的进展。
• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20130079338A1

  公开（公告）日：2013-03-28

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，是其拮抗剂，可能对治疗中枢神经系统的各种疾病有用。
• Pyridine and pyrimidine analogs of acetaminophen as inhibitors of lipid peroxidation and cyclooxygenase and lipoxygenase catalysis
  作者：Tae-gyu Nam、Susheel J. Nara、Irène Zagol-Ikapitte、Thomas Cooper、Luca Valgimigli、John A. Oates、Ned A. Porter、Olivier Boutaud、Derek A. Pratt

  DOI：10.1039/b912528k

  日期：——

  Herein we report an investigation of the efficacy of pyridine and pyrimidine analogs of acetaminophen (ApAP) as peroxyl radical-trapping antioxidants and inhibitors of enzyme-catalyzed lipid peroxidation by cyclooxygenases (COX) and lipoxygenases (LOX). In inhibited autoxidations we find that ApAP, the common analgesic and antipyretic agent, is a very good antioxidant with a rate constant for reaction with peroxyl radicals (kinh = 5 × 105 M−1 s−1) that is higher than many widely-used phenolic antioxidants, such as the ubiquitous butylated hydroxytoluene (BHT). This reactivity is reduced substantially upon incorporation of nitrogen into the phenolic ring, owing to an increase in the O–H bond dissociation enthalpy of pyridinols and pyrimidinols with respect to phenols. Incorporation of nitrogen into the phenolic ring of ApAP was also found to decrease its efficacy as an inhibitor of prostaglandin biosynthesis by ovine COX-1 (oCOX-1). This is explained on the basis of an increase in its oxidation potential and its reduced reactivity as a reducing co-substrate of the peroxidase protoporphyrin. In contrast, the efficacy of ApAP as an inhibitor of lipid hydroperoxide biosynthesis by soybean LOX-1 (sLOX-1) increased upon incorporation of nitrogen into the ring, suggesting a different mechanism of inhibition dependent on the acidity of the phenolic O–H which may involve chelation of the catalytic non-heme iron atom. The greater stability of the 3-pyridinols and 5-pyrimidinols to air oxidation as compared to phenols allowed us to evaluate some electron-rich pyridinols and pyrimidinols as inhibitors of oCOX-1 and sLOX-1. While the pyridinols had the best combination of activities as antioxidants and inhibitors of oCOX-1 and sLOX-1, they were found to be more toxic than ApAP in preliminary assays in human hepatocellular carcinoma (HepG2) cell culture. The pyrimidinols, however, were up to 17-fold more reactive to peroxyl radicals and up to 25-fold better inhibitors of prostaglandin biosynthesis than ApAP, with similar cytotoxicities to HepG2 cells at high levels of exposure.

  在此，我们报告了对吡啶和嘧啶类对乙酰氨基酚（ApAP）作为过氧自由基捕获抗氧化剂以及环氧合酶（COX）和脂氧合酶（LOX）催化的脂质过氧化反应抑制剂的有效性研究。在抑制的自氧化反应中，我们发现，作为常用的镇痛和退烧药物的ApAP，是一种非常好的抗氧化剂，其与过氧自由基的反应速率常数（kinh = 5 × 10^5 M−1 s−1）高于许多广泛使用的酚类抗氧化剂，如普遍存在的丁基羟基甲苯（BHT）。由于吡啶醇和嘧啶醇的O–H键解离焓相比于酚类有所增加，导致将氮引入酚环后，其反应性大幅降低。ApAP酚环中氮的引入也发现减少了其作为羔羊COX-1（oCOX-1）前列腺素生物合成抑制剂的有效性。这可以通过其氧化电位的增加以及其作为过氧化氢酶原卟啉还原共底物的反应性降低来解释。相较之下，ApAP作为大豆LOX-1（sLOX-1）对脂质过氧化氢生物合成的抑制剂的有效性在引入氮元素后有所提高，这表明其抑制机制可能依赖于酚类O–H的酸度，可能涉及对催化性非血红素铁原子的螯合。相比于酚类，3-吡啶醇和5-嘧啶醇对空气氧化的稳定性更高，使我们能够评估一些富电子的吡啶醇和嘧啶醇作为oCOX-1和sLOX-1的抑制剂。尽管吡啶醇在抗氧化剂和oCOX-1、sLOX-1抑制剂的活性方面表现最佳，但在对人类肝细胞癌（HepG2）细胞培养的初步实验中发现其毒性明显高于ApAP。然而，嘧啶醇对过氧自由基的反应性高达ApAP的17倍，对前列腺素生物合成的抑制效果好达ApAP的25倍，在高浓度暴露下，其对HepG2细胞的细胞毒性相似。
• NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME
  申请人：Miura Toru

  公开号：US20120046308A1

  公开（公告）日：2012-02-23

  An α-phenoxybenzeneacetic acid derivative represented by general formula (I), which has both an angiotensin II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, metabolic syndrome or the like, a salt of the derivative, or a solvate of the derivative or the salt; and a pharmaceutical composition containing the derivative, the salt or the solvate. [In the formula, Q represents a group represented by formula (II) or (III) [wherein R 1 and R 1′ independently represent a C 1-6 alkyl group; R 2 and R 2′ independently represent a substituted or unsubstituted C 1-6 alkyl group; R 3 represents a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, or a group represented by formula (IV) [wherein X and Y independently represent CH or N; Z represents a C 1-6 alkylene chain, or the like; R 11 represents a hydrogen atom, a C 6-10 aryl group, or the like; and m represents 0 or 1]; and R 4 represents a substituted C 1-6 alkyl group]; R 5 and R 6 independently represent a C 1-6 alkyl group: R 7 represents a carboxyl group, or the like; R 8 , R 9 and R 10 independently represent a hydrogen atom, a halogen atom, or the like; and n represents an integer of 1 to 3.]

  通用公式（I）表示的α-苯氧基苯乙酸衍生物，具有血管紧张素II受体拮抗活性和PPARγ激活活性，并可用作高血压、代谢综合征等的预防和/或治疗剂，或者衍生物的盐，或者衍生物或盐的溶剂；以及含有该衍生物、盐或溶剂的药物组合物。【在公式中，Q代表由公式（II）或（III）表示的基团【其中R1和R1'分别代表C1-6烷基基团；R2和R2'分别代表取代或未取代的C1-6烷基基团；R3代表氢原子、取代或未取代的C1-6烷基基团，或由公式（IV）表示的基团【其中X和Y独立地代表CH或N；Z代表C1-6烷基链等；R11代表氢原子、C6-10芳基基团等；m代表0或1】；而R4代表取代的C1-6烷基基团】；R5和R6独立地代表C1-6烷基基团；R7代表羧基等；R8、R9和R10独立地代表氢原子、卤素原子等；n代表1到3的整数。】
• NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME
  申请人：Miura Toru

  公开号：US20120028983A1

  公开（公告）日：2012-02-02

  Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R 1 and R 2 independently represent a C 1-6 alkyl group; and each of R 3 to R 5 is absent or represents H, a halogen atom, OH, NO 2 , a halo-C 1-6 alkyl group, a (substituted) C 1-6 alkoxy group, a (substituted) C 3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]

  本公开了一种化合物，具有抗血管紧张素II受体活性和PPARγ激活活性，并可用作高血压、心脏疾病、心绞痛、脑血管疾病、脑循环障碍、缺血性外周循环障碍、肾脏疾病、动脉硬化、炎症性疾病、2型糖尿病、糖尿病并发症、胰岛素抵抗综合征、X综合征、代谢综合征和高胰岛素血症的预防和/或治疗剂。【在该式中，A代表5-至10-成员的杂环芳基；R1和R2独立代表C1-6烷基基团；R3到R5中的每一个缺失或代表H、卤素原子、OH、NO2、卤代C1-6烷基基团、（取代）C1-6烷氧基团、（取代）C3-6环烷氧基团或5-至10-成员的杂环芳基。】